AGIO - Earnings call transcript Q2 2022 | Agios Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to Agios Second Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end of the call. Please be advised that this call is being recorded at Agios' request. I would now like to turn the conference over to Holly Manning, Senior Director of Investor Relations. ahead. go Please

Holly Manning

Good quarter operator. and to welcome Thank conference morning, call. second XXXX Agios' you, everyone,

You slides Medical Corporate Gheuens, Financial and of Jonathan our With Investors Dr. Section call and Chief Research can to with Affairs. Jackie of Chief going and access today Officer; Dr. Executive Officer our for our Fouse, today's our website, remarks agios.com. prepared me Officer; Sarah Chief Development; the by on and Commercial of are call Head Officer our Chief Head Richard Poddar, the Biller,

we of With to I we we and some risks, statements as our Before implied future recent get factors, filings will set events any everyone Jackie. started, to those this materially make the on may a the uncertainties with could filings most including that, like I include other statements or forth remind from the results SEC will any SEC. statements. and expressed Actual would turn in and by with of call forward-looking call over forward-looking that make differ that various result other the those

Jackie Fouse

Good morning, quarter results thanks for everyone joining XXXX our second and call. Holly. Thanks

and ever PK report performance quarter PYRUKYND, therapy which first treat on first for approved remarkably of productive other and business. our we launched first half of by lives our their to first to each all impressive will which of patients. disease and in the first approved connection impact deficiency is XXXX of kinase our our organization has cover world-class genetically continued the more the facets vision of Today, execution The Richard commercial making our to focused across been In full I've the medicine, impressed detail. be commercial Agios defined launch, February, an activator. pyruvate team FDA of the

of review In disease across has expansive robust came Hematological of of and two site our with decision employees which the in to an X the reminder Sarah programs. our offsite the will pandemic for presence and and dynamic ago through weeks we the the first the evolution clinical well PYRUKYND MDS in the me we preclinical, programs enrollment ongoing led Our organization, of A continuing team since patient momentarily. deficiency the to half culture European Meeting we pivotal as Association while interconnected an our Vienna a and the cell business studies, made studies pivotal clinical talent operationalizing and Agios R&D cell tough the PK clinical and three sickle June, start advance of Agios trial, exceptional to broad a all activation at business. pediatric cohort as was when preclinical our updates a incredible research translational It ago. AG-XXX evolve May, company continues teams for at few have and that years of occurred research together thrive AG-XXX had our and to highlight across initiated two study development integration sickle And the and our focus activities. enhanced in thalassemia disease. Phase

Directors chapter. XX over through companies. its strongly in vast and global hematology, to Brian as believe course of Chief that the Chair Turning leadership ago, role operational of few become I the will new biopharmaceutical Brian to Agios announced I right of at commercial years of the leader he of is Officer Agios. to weeks we the has and and diseases next experience will slide five. that Executive of August A rare the transition Goff cultivated Monday, X, Board guide

reason pipeline fully collective so evolve leverage Agios set move team, stage turn be we continue sheet a business. provides balance look continuing medicines to as of that resource made I we and support of of Agios planned today, in also that of to that Sarah. optionality serving and amazing CEO, working our smooth it's orchestrate reflect I'm that it Board. position its your future part the an the as Agios my in from underway, underway, as of for confidence can clinical forward a I'll to a so that positive forward each that or commercial on rare company. time significant studies for Board mission team, to continue and a Board be My play a five Monday, focused team the Starting a ability excited future. genetically team with steadfast, to of this a diseases reference, into I role and of As With that Agios have I'll him strength to the helping global in the that, you the Board management we bright the and growth immense in to we've for early our and my while as proud is individual impact make and I'm skill CEO, as pandemic of founding strategic over to his as launch, to pivotal Brian giving as and focused on for resiliency the created. a touched and remains to the Chair on the a trials a on I with now and point great of and through promising multiple colleagues decisions. our I we Standing world first-in-class into role operating preclinical lives our bold also make face learn here space future defined enviable thank a a decisions look be transition

Sarah Gheuens

seamlessly shift we in cellular that retain clinical our and/or enabled into most this acquiring well-characterized our the team This and also focused my us to our R&D and metabolism internal pursuing complements our in programs capabilities. research in to research new insights that as and is scientific pipeline strong of step research our moving increases people of that my on forward, the integrate on internal programs of in-licensing opportunities Thanks and I'm to With validated Development. expertise high strategy potential evolution announced role while and It Jackie. of development existing organization priority on efficiency commercial growing assets. functions deepens and Research patient promising focus a to decision-making. approach group Back and the preclinical a coordination and way organization resources to May, excited Head focus and the impact evolution,

we incredible and research drive talent encompassing It and organization eight, been positive and functions of impact slide on a gratifying clinical have R&D on have the an all our shown and built fully we amount forward across organization. As within preclinical programs development to a has communication the functions. these each see this way truly had already to collaboration new has of structure needed

nine. slide to Turning

focused While programs. us research business underlying are the of leaders preclinical our evaluate advancing fit at internally potential science helping thoughtfully discovered development are our work and on they also hard opportunities,

may acidemia leading a errors to treatment acidemias of quality the known a X our of inhibitor As slide the aminotransferase branched-chain these methylmalonic a also amino fewer potential These toxic life. down inhibition and the branched formation program group which acids, the has patients metabolites, as of cannot their as body PA in reduce and acids other BCATX to to metabolism accumulation. amino and restrictions break is for BCAAX propionic known earliest MMA. enable inherited shown acidemia inborn are called XX, have chain of which on dietary of improve

Our late is in BCATX lead optimization. currently inhibitor

Turning to slide XX.

life. and may patients advanced inherited quality expect intake, concentrations stabilizer PKU to IND lifelong candidate The normalizing as next the their phenylalanine accumulate. disease achieve diet Our a rare plasma development preclinical we their or the treatment hydroxylate, natural program phenylketonuria that program milestone, for increase causes of most known approaching Normalizing year. is phenylalanine and protein allow is the improving an PKU. to is of PAH, phenylalanine to

development the PK can you slide programs on activators, As have and our on both PYRUKYND for broad XX, clinical AG-XXX. we clinical side, see

a cell in to AG-XXX our XX. activator, evaluated a novel Turning X healthy slide sickle in Phase being component. currently with volunteer a disease is PKR study

ascending completed to dose ascending initiated for at and in sickle cell the Annual We part ASH this present study Meeting order data the a and anemia. multiple hope these later healthy disease We a the molecule hemolytic recently volunteer cohorts of data single have year. obtain in to this

blood In potential unmet improve cell health activation has to MDS, myelodysplastic to red in a significant where there both syndrome, believe is need. or intermediate addition, we PK the

patients study Xa of As of open-label in our in shown period. XX, continue eight week in hemoglobin extension weeks the operationalizing study MDS. proof-of-concept an parts one we in AG-XXX through the the on with AG-XXX study enroll Phase study will dose will Xa/Xb who working core is level receive complete Phase are core of MDS. component who XX-week of once for slide The Xa AG-XXX the daily baseline core as study be lower-risk will from period defined increase or burden the eligible transfusion period. in during patients The Patients concentration to deciliter hemoglobin eight equal defined or period patients The independence the grams more primary week through X.X transfusion-free the as in only. consecutive both are endpoints an response XX from for for per with equal and more transfusion average XX

and PK trial biomarkers. safety, additional look PD the initiating the forward include anemia We of and by of endpoints to end the year. Secondary measures

PYRUKYND, advanced company health hemolytic the and slide our first cell be known do we hemolytic most blood XX across clinical to well-positioned the mitapivat, for longevity, of is activator, and course distinct PK to increasing Turning this focus our are energy, to three anemia red anemia. by transform to commercially as

The are deciliter mitapivat week twice or daily XXX-milligram and increase PYRUKYND sickle first resulting exploring goal oral more reduce operationally anemia, placebo. improve X:X:X XX RISE in agents known equal of by XX X life through methemoglobin portion from daily on being VOCs reduced and concentration in disease, average slide twice hemoglobin hemoglobin of defined response endpoints we randomize to potential The adults UP quality safety. or one-gram patients shown cell matched seamless fatigue. the XX as baseline XX, study As Phase in as improve XX-milligram with and to to an increasing compared per X/X are with than pain mitapivat will in week Phase primary the

is the determination X, enrollment first Upon totality by to a the portion hemolysis, outcome secondary of other data we will endpoints. reported Phase primary and the double-blind Phase step. portion sickle year. of before of goal paradigm is With into the the complete pain will Phase cell allow portion completion in start endpoint of of septic in us the X the to also the X. Then changes end The make patients of X the the protocol. the these X Our rate this triggering evaluate a in of of Phase the take on data account we markers will success, dosing the for crisis, Phase

As for regulatory assess the Phase we aspects seamless to the we operationally phase to trial. the an can X X well to the of the as the as based outcome study, which without speed next, one transition from at have impact Phase on on increase and ability the of the need modifications statistical

to on XX. Moving thalassemia slide

trials We to therapy the global ENERGIZE-T. well across as of anemia have initiated transfusion-dependent thalassemia end [indiscernible] thalassemia. transfusion-independent PYRUKYND, oral pivotal alpha hemolytic establish to last two the the potential year, very our are as and PYRUKYND data placebo-controlled we At and ENERGIZE excited and and first as of ineffective to improve

endpoint to milligrams mitapivat twice equal are or beta not defined patients baseline. regularly As placebo X-gram twice compared in response XX-week blood is to milligrams a to a hemoglobin with in week in evaluate equal defined hemoglobin units during a XX% baseline. as period thalassemia daily both daily unit units will transfused. placebo both reduction red through red than XXX to blood alpha of and X:X week more patients six transfused with of The transfused randomization. weeks regularly cell of or transfusion transfused prior X:X XXX ENERGIZE concentration week from The or and defined XX patients reduction will consecutive to or blood compared mitapivat deciliter more transfused, randomized the response who randomized XXX cell evaluate XX two alpha a red or primary as reminder, endpoint cells an XX who primary beta per XX any average in greater are ENERGIZE-T thalassemia reduction in XX increase with XXX of patients of

of end patients continuing by portion Our of and is site patient in team year. to the a meaningful in enroll on focused enrollment global the activation studies both efforts order

our Finally, slide deficiency expand in PYRUKYND medicine receive and February, evaluate PYRUKYND by In track to PK over marketing ages patients. regularly for ACTIVATE-KidsT the either two programs. utility key Officer. randomize our for of decision turn the and against XX, will PYRUKYND hemoglobin review on as response will EU, or deficiency over to in up summary, all the call PYRUKYND period. one transfused to all parallel, PK the as patients we we pediatric not June, XX, became initiated XX to we With to to XX, or the application our the shown now placebo X:X deficiency remain patients, XX. Richa, will quarter first made kinase our XX-week pyruvate under stations In randomize on reduction evaluate PK core shown placebo regularly that, remains period. Chief XX-week transfused over this are and year-end. deficiency transfusion with course progress this continue of EMA adult FDA-approved milestones the Commercial therapy either PYRUKYND from across we authorization pleased in in I on studies a efforts to slide XXXX In ACTIVATE-Kids X:X the and

Richa Poddar

the Thank million. U.S. net launch, of PYRUKYND which of Sarah. generated sales the In $X.X represented you, second quarter, full first quarter we the

before, facilitate XX commercial product disease to slide our provider As for strategy we've information said the connect outlined with appropriate aims launch patient. on and the to access and

drive the services the and disease PK received what U.S. we diagnosed slide accurately patients launch are ensure that to ID; we so view under for understanding, full first is have urgency focus second, early long-term physicians from observed efforts and X,XXX have the and in are medication finally, deficiency physicians. access encouraged by patients meaningful myAgios we X,XXX patients we connect our the far on metrics Our patients prescribe the support as advocate adherence. belt, as first, I'll well as With quarter feedback Anemia outlined ensuring, to through the with metrics as understand start the like an our approximately to eligible optimize treatment; XX. on to key

patients customers of anemia specialists on scripts As new with now enrollment been continued This with completed our includes of in hemolytic total prescriptions continuing unique prescription and to XX XX, forms. which June they those team have with XX as PYRUKYND has driving to have PYRUKYND, are and successful a patients engage those of converted total treatment.

diversified launch, early health. of prescribing prescriber centers Importantly, XX across launch a centers excellence. at unique this stage from patients of and community validating physicians the these patients are of The the treated academic in of our or that versus states coming early the are of practices country, indication medical across view base with of breadth majority

patients, As a patients hemoglobin. regularly very and old that and not quarter, non-splenectomized young and first a we various characteristics levels regularly on splenectomized patient that patients coming represent population. saw in These transfused, disease patients the and therapy and of representative have range patients the of adult of PKD demographics of includes range are

In national terms positive interactions have to our with payers continue directors of date. dynamics, account payer to

the As scripts clinical statement developed few in we through exception starting aligned process been policies developed. criteria. of in indication policies to payer the are or saw the the be to are have QX, eligibility majority place approved as with Payer medical trial

Turning to slide XX.

hemolytic with in positivity in PK remains XX% those is diagnosis We a the genetic and with our an they general Of deficiency for for been the etiology. have program designed ordered, Anemia tests with positive to which percentages. X,XXX adult last unknown a pediatric are completed More mid-single-digit Consistent QX. testing have free been between diagnosis of completed patients interest accurate pleased anemia the kits continued since quarter, kits rate ID of than drive and of increase XX% evenly tests, are the approximately a split kit, patients.

to there early Looking to consider trends. several to are the second year, of factors we continue half as launch the evaluate

label XX% we six experience, of levels, trial and treatment assessment First, on hemoglobin suggests on point of response based Based responders function. will our approximately at hemolysis continue individual clinical be believe which made. be patients markers on for patients an deal considered can XX% to of months, and of assessment our

the reach will the six-month we launch, off to mark come non-responding of therapy. we see As start patients

patients on who For make and be therapy, stay the we able will to persistence. of adherence better assessments

coverage. Second, approximately as optimal achieve launch, to payer we to year said prior take it will a

statement, as the slide right-hand The policies continue which chronic developed, response the define important are payers clinical trial for they are on We including as And box process. rare initial part not poorly will indication is PK which in second to as coverage, to for how XX, us is eligibility. payer could track deficiency for remember a based the the understood. exclusions noted is be criteria and individual which the reauthorization condition, it as that well of finally, on

around efforts be team education multiple The disease initiatives, that commercial to requires ensure both a long-term paramount laser-focused on to to disease is success. given accurate diagnosis on also create and to and urgency is interactions deficiency continue ensuring educate accurate encouraging Our diagnosis. that these disease PK

experiences deficiency launch encouraged community. these very with the successes broader PK creating are We and positive we early the are with

on our impact we built is organization experience be passionate significant and strategy fully with and disease rare commercial for We of are grateful deficiency a PK have lives of that excited executing the capable making the patients.

now genetically second defined quarter other Jonathan applicability well all it diseases. seeing as are our longer deficiency connections up expand to With eligible is to this knowledge PYRUKYND base success from making financials. us PK that of as we launch Importantly, for strategy, and continue review to commercial we setting we I'll that, over term the turn as are the our what are to patients,

Jonathan Biller

Thanks Richa.

results financial press this morning, detail issued be XXXX included More I our will filing will today. XX-Q later which in found can quarter second release the be summarize. Our we in

Turning XX. to slide

the PYRUKYND was shared, for quarter revenue second Richa As $X.X million.

million intellectual upfront addition, Friedreich’s was $XXX,XXX. the In licensing of had of associated the our recognized for XXXX. the Ataxia revenue in to quarter in $X.X quarter sales preclinical which payment an with with Cost for of we property we discontinued respect program,

positivity equivalents to billion. was for securities reimbursable and With and to $X.X under the completion Phase we and X primarily spend concluded Phase is and questions. with catalysts and was expense We of to PK first the program, headcount raise cash, provided for preclinical PAH AG-XXX the in additional an Turning the gain the able quarter business, cash quarter activity Xa $X the need on second a million $XX.X the which for With current $XX.X in transition-related statement, that, planned over year-over-year balance, second business with decrease of administrative quarter, to increase in quarter studies major quarter increased to TIBSOVO the by R&D XXXX. recorded for line of was approximately primarily was execute study, sale of quarter royalty in expense. start-up expenses the development without sickle operator, to to which increased SG&A of second AG-XXX the on MDS costs expect decrease income revenue, costs compared open through PYRUKYND for to the to our million, and expenses, ended Research royalty cash Selling, be income flow equity. deficiency. driven increase of increased the due plan The operating and trial services this related start-up associated and XXXX. of workforce $X.X the operating related cell million XXXX. please million Servier disease were cash oncology oncology $XX.X our marketable The pivotal second sale million. general representing the pediatric for

Operator

Thank Frahm you. [Operator Marc with Our first from Instructions] Cowen. question comes

Your open. line is

Marc Frahm

expect of through Yes. in come do time Maybe you Thanks that year? to patients taking on the kind Richa. seeing on full to you the forms trajectory of the for question Can drug? those you're And quarter. the the for have that XX congrats and that speak how is versus start rest XX change kind on the of this

Richa Poddar

Marc, Yeah. question. thanks the for

we also well. are drug, the So, seeing patients the we drug as on to as both regards that encouraged, are getting but we getting the with drug the access said, trends -- to getting in

point that So, to about expect taking we exception the are those medical therapy, developed. to policies It's process, time. four still given patients get for payer have transitioning over eight convert to on we been this through at

steady As we is including we've said second that anticipate this the in the past, the launch half. and way slow

The things think to through are titrating I here. therapy. keep still mind two patients their in

our to our had respond. we have as We label, be on patients according about depending what know the to least where response of assessment second as XX% we that So, developed, then, know well And we the policies of will six patients half payer the it's assessment to the at from that, patient. for in some XX% the months sense, drop-off. expected made of more authorization like. and And terms looks clinical

as we are getting the to breadth into with but consideration encouraged two trend those country. terms as the of across of who drugs to patients the the just in early are half, the are second diversity well this very prescribing So of as launch both prescribed into take go we things

Marc Frahm

I open And the on reauthorization to then, feedback of that criteria how new those looks pretty the the are is authorization process versus regiment you're adhere strictly maybe the being early trial helpful. to Okay. but a process, interpretation plans That's you response seeing criteria know a the getting broader in what early, response like?

Richa Poddar

with the it's we will is as continued and think to do a as reauthorization to really continue to management is rare criteria as going the here's disease, between I conversation utilization right? engagement and important. payers, very do this is develop That and our have the division which well so the think continued -- plans, those be I So,

but it been hope have far thus continues Still like the it direction interactions we I to in those too So, would. positive. early said, trend comment,

Marc Frahm

you. Thank Great. Okay.

Operator

comes Gregory Renza with from question RBC. Our next

open. is line Your

Unidentified Analyst

question for [indiscernible] on follow-up the and congrats just for our on Greg. taking questions Maybe the quarter. patients a Thanks is PYRUKYND. on on This

Just new quarter? ID. what growth that this kit, XX, Anemia expectation about? many wondering we some headwinds and And among the half? just secondly, tailwinds And should the around diagnostic what then second think in of on are And the were patients NRx your added how the the is

a the Or is increase prevalence? that you rate other of Thank long evolves in positivity do a rate there are the function And wondering, Just factors where you. can that rate? see to positivity time?

Richa Poddar

Sure.

So, question I'll first. the ID answer Anemia

positivity because pretty just reported the point pretty for we So, it's we the rate believe steady that we where while. has are and a been at steady

As for not we deficiency period. what a it well ID healthcare and to improved base is our of with right? specifically, the reminder, anemia Anemia designed needed as for knew as professional PK diagnosis We have designed hemolytic was physician needs

anemia to for to PK understand unknown what test hemolytic efficiencies. to to to of anemia specific healthcare and cost is being professionals opposed designed for the etiology So, underlying hemolytic aid the as

would rate don't we positivity PKD have any to specifically. we information expect with suggest this minute, of in upward any associated as So, mobility the

So that's on NRx Anemia it's early comment. again TRx, versus ID. To question on to really your

we important is seeing steady and are think slow we I that what growth is anticipated. as

patients wide of We are seeing variety demographics. a across

general. any earlier what as that second in is full I -- expect in the rare a the we're Again, encouraging which are would disease, adult how representative that quarter. is also specific half, of kind the in disease disease, concentrated so correct is chronic across very is a nature which with you encouraging, levels, centers lot this said base is PKD across excellence, not and being off hemoglobin seeing across well, reminder, of is you population, seeing first which would expect. we our We characteristic as patients of a in prescribed, country, This not as the

So, still very early. really,

shaped We for the to have efficacy long the a which looks XX% to utilization then to is XX%. out. take But with a And like, that management up, well. and six-month going in figure assessment the to us in reauthorization criteria to where we clinical will was how terms trial, influence also see that what time get payer policies of which happens it see have real world as

fully have but more what just it's we heading like couple sense the quarters, So, to of to is opposed encouraging. of as more we which right trends direction, have a

Unidentified Analyst

Great. Thank you.

Operator

We with have from SVB Berens Andrew Leerink. question a

is open. Your line

Andrew Berens

thanks give launch Congrats of and on Hi. one on wondering if on the their was that us opportunity. opportunity for are PKD the market. then, program in color cohort? stopped genotypes the commercial also patients the that I that has on some PYRUKYND? the the giving color you progress now transfusion Any independent on And addressable thalassemia could on Bristol thoughts

Richa Poddar

Yeah.

terms a right, can obtained in enzyme a reminder, PK genotype, diagnosis as the of be so So, or deficiency through testing. testing genetic

thanks this and So teams but done. label, remember have are that we at And of seeing all pretty to regulatory always the not -- moment. information clinical for for work have the as patients, broad, physicians don't genotype the our PYRUKYND we you from our our label

it is for prescribed patients. PKD So, adult

the currently we long in and trend. you're are As seeing of terms of PYRUKYND, prescription eligible our age XX, what for over as that's

going least And have. seeing to the same well. base Sara news. a these couple a then prescribing as see and on experiences of to healthcare with right give professional very clinical because positive it's physicians and physician we that to drugs good not be seeing will genotypes. We're not we the only that's your question already also generate not around So to at standpoint are it encouraging from things that of -- starting We're thalassemia comment thalassemia, on and looking PKD, it But thalassemia. then that that in at a kind certain to I'm a say, so or give as it genotype certain to data mentioned, we you ask for oh,

have they the So, an get, the the we the better drug, space. approval the when setup in more thalassemia will better be with they have we we experience experience

you to thalassemia. therapy that small in with a served benefits feel still address the a benefit need really the transfusion-dependent value we which we data good And overall. of transfusion-dependent designed there's by we data, see and oral as And alpha as they that designed from proof-of-concept all believe proportion consistency including across that luspatercept, the a know stead population, as whether is is itself, and function looking which a that a of only physicians heard both We've a that's we've lot don't non-transfusion-dependent currently an itself program well. beta from that the that is is convenient. totality people at program across tremendous hemolytic Our of well respond. clinical our was something anemias, And three spectrum of thalassemia of as wide patient very

encouraged seeing, very with plan. development but comment on we Sarah what the are can we clinical So, are thalassemia more

Sarah Gheuens

Thanks Great. Yeah. Richa.

but remain the we from the this thalassemia. to we've development on And track programs, non-regularly difference as an planned our program do with an of population, Richa the decision described on data of totality data package across -- mechanism on on on very a yes, been always program reasons, hemoglobin, for top not and overload. probability as increase We different. mechanism of also mean, see of of for action So, couple drugs or transfused encouraged both do generating including the impact earlier. our of our and because then we've seeing see clinical is signs -- our starting different impact I to of the for transfusion having success. action clinical on iron perspective, that, recent And deliver of our that

same the to forward We and continue programs probability with move of believe success. our in to continue

Andrew Berens

VOC. question Thanks Jackie Maybe Thanks. on a Great. that. for for

question. considering You that's Or aren't for Thanks Appreciate GBT? just joke? it. a Are acquiring you? taking the guys

Jackie Fouse

How in I about that. if to response laugh

Andrew Berens

Okay.

Operator

question comes from with Oppenheimer. Mark Our next Breidenbach

Your line open. is

Unidentified Analyst

Mark taking the question. for and in Congrats for from on Jaclyn quarter thanks is This our Oppenheimer.

What monthly retention in issues? seen have to new you payer is abatement first any one prescription scripts? due the XQ? how And related The was many rate

Jackie Fouse

hear didn't your the I of Yeah. but your I'll come part second maybe first back answer part question. question, the then to first and

So, about abatement I asked maybe. think had you

they -- we have seen program event a once So, What drug then is been delaying haven't our we few enroll therapy which staying to a or with therapy, patients again, support therapy. on what in getting into patients start patients that high-touch therapy. have are take want patients really necessarily a is terms while is not of we also -- wedding patient like anecdotally started they've been myAgios of a that have patients really life holiday. some and prescribed helpful therapy on been We've seen prescribed our

therapy, are know So, a are at early question first stage. don't this sorry. I'm but their waiting on seeing I they stopping not we your what was,

get. So if quite could didn't repeat you I that.

Unidentified Analyst

Yeah.

new So, And quarter? what second monthly many the for scripts? retention rate was the how

Jackie Fouse

includes haven't those new and scripts. patients as XX XX continuing have we like previous this this we on filled, have we which that on that said initiated been specifics well in have the those So, quarter. as prescriptions, What those quarter of both provided have from are is,

Unidentified Analyst

trial. RISE my on Thanks. the UP other question Okay. And is

the of the portion see we the we year-end. response, a dose half And as enrollment Can well? in Phase focused on some or complete the XXXX? solely of hemoglobin safety UP expect to data X in selection from and endpoint by decision could With RISE trial of secondary what study data first the initial the

Sarah Gheuens

this Hi, Sarah. is

see a weeks. of So, will period the has follow-up trial quarter not -- in the you XXXX, XX because first Phase of the X data

need patients the need to complete go database then lock data. that, follow-up, all through review to safety So, their and do the we

we're to for so the presentation. possible safety data we you secondary the that response and going to in happen in just not obviously, Phase then will that in we're data, have than in be our X just that collecting it's all collect more I've regards -- it's QX. the the and hemoglobin to outlined because that -- And seeing, of endpoints the So, do

be will go, to as for the criteria well. dose the all we pre-specified inform then and decisions so, to there our Phase data And selection no-go X are analyzing of

we from when very focused X will moving ready, on be Phase more towards to year. the we'll hope of but X, data be Phase we much be the have medical the conference end will at an upcoming We presenting which that

Unidentified Analyst

helpful. Thank congrats Great. much and That’s on you again so quarter. the

Sarah Gheuens

Thank you.

Operator

question We have with Salveen Goldman Richter from a Sachs.

open. Your line is

Unidentified Analyst

to identification? about and taking Salveen our launch PKD? Could Or efforts identify you same expand to for This utilizing ID suitable thinking are do And of PYRUKYND new thanks on is the question. many efforts patients? to the And test PYRUKYND are Are on patient how trajectory positive continue how most the the treatment? think Anemia actually to are on you for [indiscernible] patients planning you you. the expand in are opportunity, lastly, sickle that specifically you for move and PYRUKYND? cell, of PKD you group patients with Thank market which

Jackie Fouse

Yeah.

So, I'll start then with backwards. maybe and work ID Anemia

a So patient been that patient, a has identified no which from that first for physician which as way know of remember all, is to. belongs to I patient think standpoint, it's just that really there PKD important us compliance to

it's kinase designed help diagnosis that time. community, in diagnosis get just drive been pyruvate that's patient anemia really is their is to we as anemia unknown seen treatment. of test now the hemolytic specific in community on tailor improved with seeing can diagnosis, of so test, and And at a important and not to doing that kinase well but and comes treatment the that needs they have to their in for over where do depending theology, again, it's growth disease from for the one there hemolytic to anemias, the continued continue differential the kind utilized. value ID, awareness Anemia So, We're least on being of we hemolytic which because the deficiency, the has. a patient of the those is of as the utilization the has the pyruvate differential deficiency,

managed kinase deficiency, throughout is is with again, an of community. largely regards diagnosis, centers diffused pyruvate it's underlying When sort and specific concentrated to chronic a just is country. the comes about it think to think I It So, itself. to I important thing is excellence. It this it's think not from rare of ID the condition, it in Anemia that's -- the

which consideration, that community of the diagnosis continue drive the ensuring be to this a true our for we so, thing, knowledge burden be learn working the to awareness are that broader the continue our diseases. disease about around foreboding And rare to efforts, understanding we but raising taken if going the it's it's closely and space, we are launch to in colleagues with disease to and medical is going a to going to very disease our into have on educate ensure sharing with of disease, continue disease,

and we that ensuring progress then product space going I get them nice think And eligible what will throughout. is that Sarah, get Phase that's in on and with are focus slow RISE for so you well. And to regards those have about differentiating that steady to how treatment do we as UP? comment our seeing sickle diagnosed in to to because patients Sarah specifically on design a continue segue that and are we X to actually be cell, trial to our want about talk the be

Sarah Gheuens

Sure.

other trial X, the secondary without which allows that adjustments Phase response seamless Phase data sense them seamless and as allow that, sickle the having it is And patients the allowed statistical X move data make moving physicians discussed in well, cell that of RISE the trials, or of any that it component mix set up get disease and still quickly and the us to it the operationally us and sickle on us both disease bring on the us for component meaningful hopeful and sites on the with that and to testing, then primary design giving X. and but disease, would data to we both right? that it's also an make is two analyzed hemoglobin cell components -- into an the for interpret the hit ready trial. us we endpoint UP forward to regulators. RISE us story VOC, in needed anemia a and need then which trial our a that of treatment as It's to endpoints, is for context because gives actually a pain So, does entirety. sickle The to beauty flexibility Phase just of very The to possible, Phase X endpoint, bring regulatory similar as allows of on allows X totality if of from us lot it impact operationally one, cell for UP basically enrollment we're on to early very Phase the crisis important as

Jackie Fouse

what the one and the the how and would right, we've sickle everything and input based study are designed clinical And we add thing to broader to the accordingly. then Sarah needs us, on are just cell community I from the thinking community what studies has differentiate that patients design about physicians understand said, told the

study determination we for concerned, we're as the success. it is to any the that, the up but we As on commercialization are that totality data far before the make depends designing ensure around set

Unidentified Analyst

you. Thank

Operator

a We Raymond with question Brill from James. Instructions] have [Operator Danielle

Your line is open.

Danielle Brill

question. prior, so Thanks morning. another just couple Good ask guess I'll a Hi. for for much I follow-up of a way. the maybe to

sequential guess you. growth the Given XQ? there your how expectations be color some thinking I a more added provide about six-month patients might I'm on on at just Thank you revenue wondering great? should potential if was in could impact if mark, we growth, XQ in that would discontinuations be bolus of that

Richa Poddar

PYRUKYND. filled. XX noted, prescribed four to prescription been we've have to right, taking for patients as the It's eight have we be So, weeks that

as as which have have that those have now, XX those that include We initiated on therapy well right refills. therapy

the So, titrating drug. through they're

not more at specifics a we're going lot Again, is -- point. first is be quarter that this that's So to our and full of learned. any on into this more launch

We how they're hold a learn. are learning strategy, from working, are lot messages and are continue to we are what what messages already are our and working, not patients responding continuing to physicians, seeing to

that So will an process. be ongoing

comment early very to anymore. So,

Jackie Fouse

was in can actually there just of patients no QX. And we bolus patients Majority joined everybody, in QX. remind think I of also

and our is think launch starting and what and being always and I but disease commercial awareness of And to getting building to we've be to And QX. patients is team pay so, diagnosis off that starting with and continue as a it's bolus traction on. talked slow we're this no to going progression, back work steady see terrific this steady about we're the gaining a in think market I

Danielle Brill

Understood. Thank you.

Operator

America. a have Greg from question We with Harrison of Bank

Your line is open.

Unidentified Analyst

for question. on taking Mary for is Thanks This our Greg.

quantify the with to long as could you you would diagnostics maybe you. awareness planning awareness the the this Maybe increase of Thank that increase? take? And of you treatment How been and PKD how have this are the increase this? PYRUKYND. to You seeing or such expect mentioned

Richa Poddar

about think in focused you centers ultra-rare a when again, it's the so excellence. disease, of -- right, is chronic that's I advantage, think this So, not rare disease,

see So, lot it's a going we take of around we time is before effort going. trends where provide and able any awareness the to specific to disease are

One therapy. today's have a PKD of you on we've a call. we is -- -- get talked we broad patients at today indicator what PKD guys think adult patients about seeing that is, leading swath I to are

the We are out spread country. that is throughout this seeing

means get are well them. awareness that with get professionals and to working, and able therapy raise country, as across that on physicians our across awareness the has patients country are efforts we So as the get

to again, kits, addition, of In key designed growth on which hemolytic improve are is of one also time. which, we with is diagnosis diagnosis start seeing ID the anemia our unknown -- Anemia hopes etiology, our our help ways slower over to with of help

So things both of the those in will long-term. help

peak As be we -- are and a that XX% believe we get number reminder, and to PKD about XX% to seven take to today years about expect patients there. of at diagnosed, five that of XX%

number the fact in nature see are the while given any that comment But and on. the the right of could direction. you it's the not reasonably concentrated, it will -- that So, disease trends we a be therefore,

Unidentified Analyst

Thank you. Great.

Operator

questions queue. for I'd like the call back There's management the turn for no any to in other remarks. closing

Jackie Fouse

morning. Thank questions you, the and this thank you, operator, everyone for

indications. As across Agios in patients, caregivers and so and in always, also my to participating for passion to especially trials the wrap and with patients. like a I making all ways I our difference partner their of those for thanking for up physicians who us clinical want many dedication thank would colleagues

are the also Our our memorialize as in everything that to connections great role a for launch quarter ongoing first team take defined second just have to such need gratitude fuel for Agios stakeholders our our across and and people with doing. efforts our for to quarter last with It's my terrific they're again full for call this amazing CEO innovation diseases. collection impact just and a express our U.S. results as my as are so And that and quarterly additive the I moment many genetically PKD of for as in an role new amazing And as bring team joining comes being the Chair set Brian into Board, moment. of for I grateful transition with in adults about our PYRUKYND view this the the Agios team very a to as of the remain and terrific there part thing the he in in this just I I'm CEO skill into team. things

support. a that, all your Thanks with Thank and future look to forward your ongoing many very terrific forward of us to past to you for I Agios. support come for So, for good and looking quarters in the today. much joining

You disconnect. may now

Operator

concludes you conference call. for Thank participating. This today's

disconnect. now may You

Agios Pharmaceuticals (AGIO) 7 Aug 222022 Q2 Earnings call transcript